| Patient | Mary McLeod Bethune |
|---|---|
| Date of birth | 1953-07-10 |
| Identifiers | MRN HR-ML043-SYN; SSN (made up) 000-43-2195 |
| Document date | 2026-05-04 |
| Author | Viola Harrington-Mbeki, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Six-week asthma review. [S]
Mrs. Bethune returns six weeks after starting budesonide-formoterol. Her nights are better, waking once a week, but she is still breathless on stairs some days and has used the inhaler as a reliever three or four times a week. The dose counter shows she has taken about 70 percent of her maintenance doses: she sometimes forgets the evening dose when she is working late. She saw the ear, nose and throat specialist two weeks ago; nasal endoscopy showed chronic rhinosinusitis without polyps, and her nose is clearer on the steroid spray. Heartburn has gone on omeprazole. Home blood pressure averages 132/78. She has had no ankle swelling on amlodipine and no muscle aches on atorvastatin. She has had no thoughts of self-harm. [S]
| Element | Detail |
|---|---|
| Control | Asthma Control Test 18; night waking once a week; reliever three or four times a week |
| Adherence | About 70 percent of maintenance doses by the dose counter |
| Ear, nose and throat | Chronic rhinosinusitis without nasal polyps on endoscopy |
| Home blood pressure | Average 132/78 |
| System | Result | Finding |
|---|---|---|
| Respiratory | Positive | Night waking once a week; breathless on stairs some days |
| Ears, nose, mouth, and throat | Positive | Nose clearer; smell a little better; no hoarseness or thrush |
| Gastrointestinal | Negative | No heartburn on omeprazole |
| Cardiovascular | Negative | No ankle swelling, chest pain or palpitations |
| Musculoskeletal | Negative | No muscle aches |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Albuterol 90 mcg/actuation inhaler, two puffs as needed, from an urgent care visit four months ago (used alone, without an inhaled steroid) | Two puffs every 4 hours as needed; she uses it most days | Respiratory tract route | 2025-11-03 to 2026-03-23 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 2026-03-23 to 2026-06-15 | completed | S |
| Fluticasone propionate 50 mcg/actuation nasal spray, two sprays in each nostril once daily, aimed away from the septum | Two sprays each nostril daily | Nasal route | 2026-03-23 | active | S |
| Sodium chloride 0.65% nasal spray, two sprays in each nostril up to four times daily before the steroid spray | Two sprays each nostril up to four times daily | Nasal route | 2026-03-23 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Atorvastatin 20 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Omeprazole 20 mg delayed-release capsule, one capsule daily 30 minutes before breakfast for eight weeks | One capsule daily before breakfast | Oral route | 2026-03-23 to 2026-05-18 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-04 | Body height | 163 | cm | S |
| 2026-05-04 | Body weight | 87 | kg | S |
| 2026-05-04 | Body mass index (BMI) [Ratio] | 32.7 | kg/m2 | S |
| 2026-05-04 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-05-04 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-05-04 | Heart rate | 76 | /min | S |
| 2026-05-04 | Respiratory rate | 16 | /min | S |
| 2026-05-04 | Body temperature | 36.6 | Cel | S |
| 2026-05-04 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-04 | Total score [ACT] | 18 | {score} | S | ||
| 2026-05-04 | Potassium [Moles/volume] in Serum or Plasma | 4.2 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-05-04 | Creatinine [Mass/volume] in Serum or Plasma | 0.94 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-05-04 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 64 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-05-04 | Cholesterol [Mass/volume] in Serum or Plasma | 170 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-05-04 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 57 | mg/dL | 50 mg/dL or more for women | Normal | S |
| 2026-05-04 | Triglyceride [Mass/volume] in Serum or Plasma | 126 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-05-04 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 88 | mg/dL | <=99 mg/dL | Normal | S |
Vital signs recorded on 2026-05-04; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; weight 87.0 kg; blood pressure 134/80, pulse 76; oxygen saturation 97 percent |
| Mouth | No thrush |
| Respiratory | A few expiratory wheezes on forced expiration |
| Extremities | No ankle edema |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Wheeze, cough and breathlessness for four months: waking with cough and tight chest two or three nights a week, breathless on one flight of stairs, relieved by albuterol, worse with colds, dust and strong scents; known asthma for many years but never confirmed by lung function testing and never treated with an inhaled steroid. Asthma, COPD and heart failure to be distinguished: spirometry with bronchodilator response, FeNO and an echocardiogram booked | resolved | confirmed | R06.2 | S — Synthetic presenting problem anchored to her documented chronic asthma. Superseded by the diagnosis at the second visit. |
| Blocked nose, thick postnasal drip and a reduced sense of smell for years, worse in the last year; no nosebleeds; never seen by an ear, nose and throat specialist | resolved | confirmed | R09.81 | S — Synthetic upper-airway symptoms; superseded by the diagnosis of chronic rhinosinusitis after nasal endoscopy. |
| Gastro-esophageal reflux: heartburn and an acid taste two or three evenings a week, worse after late meals and lying down; no trouble swallowing, vomiting, black stools or weight loss | active | confirmed | K21.9 | S — Synthetic comorbidity of asthma; not a claim about her real health. |
| Obesity, class 1 (BMI 33.1); she wants to walk more and to keep up with her work, and agreed to talk about it | active | confirmed | E66.811 | S — Synthetic comorbidity recorded in her words and with her agreement; not a claim about her real weight. |
| Asthma, confirmed: variable airflow obstruction (FEV1 64 percent predicted, rising 270 mL or 21 percent after bronchodilator, with a normal post-bronchodilator FEV1/FVC of 0.72 and normal DLCO); type 2 inflammation (FeNO 46 ppb, blood eosinophils 0.42 x10^3/uL, total IgE 210, house dust mite sensitization); not COPD and not heart failure. Uncontrolled at diagnosis on albuterol alone | active | confirmed | J45.40 | S — Synthetic modern confirmation linked to her documented chronic asthma. |
| Hypertensive heart disease without heart failure: clinic blood pressure 152/88 and 146/86, home average 144/84; mild concentric left ventricular hypertrophy with grade 1 diastolic dysfunction and a normal ejection fraction (62 percent); BNP 48 pg/mL | active | confirmed | I11.9 | S — Synthetic finding of the modern work-up; not a claim about her real heart. |
| Hyperlipidemia: LDL cholesterol 144 mg/dL; 10-year ASCVD risk above 20 percent with hypertension | active | confirmed | E78.5 | S — Synthetic cardiovascular risk factor. |
| Chronic rhinosinusitis without nasal polyps: years of congestion, postnasal drip and reduced smell, with mucosal swelling and mucus in both middle meatuses and no polyps on nasal endoscopy | active | confirmed | J32.9 | S — Synthetic upper-airway comorbidity of asthma; not a claim about her real health. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | Asthma Control Test, symptoms, night waking and reliever use | Every visit | Completed today | Asthma Control Test 18; night waking once a week; reliever three or four times a week |
| Examination | Inhaler technique with her own inhaler, and adherence | Every visit; before any step-up | Completed today | Three errors (not shaking, fast breath in, no breath-hold) corrected with a spacer; adherence about 70 percent by dose counter |
| Self-management | Exacerbation history (oral corticosteroid courses, emergency visits, admissions) | Every visit | Completed today | None since the last visit |
| Self-management | Step-up or step-down assessment (GINA track 1) | Every visit | Completed today | No step-up until technique and adherence are corrected |
| Self-management | Written asthma action plan | Every visit and after every exacerbation | Completed today | Reviewed; peak flow diary to set her personal best |
| Self-management | Triggers, exposures and smoking or vaping | Every visit | Completed today | Dust mite covers in place; avoids perfume at meetings where she can |
| Imaging | Spirometry after stabilization | Three to six months after starting treatment | Due | Planned for the next visit |
| Examination | Comorbidities | At diagnosis and yearly | Completed today | Chronic rhinosinusitis confirmed; reflux settled |
| Examination | Blood pressure in clinic and at home | Every visit; home readings at diagnosis and after changes | Completed today | Clinic 134/80; home average 132/78 |
| Laboratory | Potassium and kidney function after starting treatment | After starting or changing antihypertensive treatment | Completed today | Potassium 4.2, creatinine 0.94, eGFR 64 |
| Laboratory | Lipid panel after starting a statin | Four to twelve weeks after starting, then yearly | Completed today | Total cholesterol 170, HDL 57, triglycerides 126, LDL 88 |
Goal progress:
Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and hypertension monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025)
Follow-up: Next planned review in about three months, sooner for any change. Call the clinic in the yellow zone of her action plan. Next scheduled visit 2026-07-27: review six weeks after an exacerbation: control, repeat spirometry and FeNO, biologic assessment, blood pressure and the post-exacerbation plan. [S]